المؤلفون: Muragendraswami Astagimath, Raviraja Aryapu, Vishwanath Patil, Suman Doddamani

المصدر: APIK Journal of Internal Medicine, Vol 11, Iss 1, Pp 33-36 (2023)

مصطلحات موضوعية: covid-19, c-reactive protein, lactate dehydrogenase, Internal medicine, RC31-1245

الوصف: Background: Appropriate diagnostic markers play an important role in categorizing COVID-19 patients with respect to the severity of the disease. Aims and Objectives: The aim and objective of this study were to compare C-reactive protein (CRP) and lactate dehydrogenase (LDH) in intensive care unit (ICU) and non-ICU patients of COVID-19 disease. Materials and Methods: Data was collected from the COVID-19 laboratory (n = approximately 3700). The patients were divided into two groups: ICU and non-ICU. The levels of CRP and LDH were estimated by the microslide method based on an enzymatic heterogeneous sandwich immunoassay. Results: In the ICU group, patients above 50 years were four times in number compared to patients below 50 years. COVID-19 infection was twice more common in males than females. The mean CRP levels in the ICU group were higher compared to non-ICU group, and this difference was statistically significant. LDH was elevated significantly in ICU patients compared to non-ICU patients. Conclusion: The study concludes that patients aged above 50 years are more prone to develop severe COVID-19. Men are more susceptible to develop severe COVID-19. The most evident finding of this study is that among patients below 50 years, higher CRP levels can be used as an alarming marker in predicting severe COVID-19 disease. We suggest that LDH can be used as a marker to predict the severity of COVID-19 disease in all age groups. We also suggest that in patients above 50 years, it is better to use the combination of CRP and LDH in the assessment of severe COVID-19, rather than using CRP alone.

وصف الملف: electronic resource

العلاقة: http://www.ajim.in/article.asp?issn=2666-1802;year=2023;volume=11;issue=1;spage=33;epage=36;aulastTest=Astagimath; https://doaj.org/toc/2666-1802Test; https://doaj.org/toc/2666-1810Test

الوصول الحر: https://doaj.org/article/9ddc74687715490eb21059b606532575Test

المؤلفون: Muragendraswami Astagimath, Suman Doddamani, Vishwanath Patil, Raviraja Aryapu

المصدر: Medical Laboratory Journal, Vol 16, Iss 6, Pp 40-44 (2022)

مصطلحات موضوعية: covid-19, covid-19 vaccines, pandemics, Medicine

الوصف: Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study was performed to compare the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) responses after first and second dose of coronavirus disease 2019 (COVID-19) vaccination. Methods: This cross-sectional study included 60 people who were vaccinated with the AstraZeneca vaccine at Karnataka Institute of Medical Sciences, Hubballi, India. The subjects were divided into two groups. Group I included 30 people who had received a single dose of the vaccine, and group II included 30 people who had received two doses of the vaccine. Exclusion criteria included having a history of influenza like illness/severe acute respiratory infection/proven COVID-19 infection in past 6 months. The antibody response was measured by the Anti-SARS-CoV-2 IgG test using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack. Results: We observed that 97% of the subjects had reactive IgG antibodies after receiving two doses of the vaccine, whereas only 83% of the subjects developed antibodies after a single dose of the vaccine. A positive correlation was observed between the development of reactive antibodies and the duration between the first dose and the second dose (r=0.24). Conclusion: Based on the results, the two-dose vaccination with the AstraZeneca vaccine is beneficial over the single-dose vaccination for protection against COVID-19. Moreover, increasing the duration between doses might improve the antibody response.

وصف الملف: electronic resource

العلاقة: http://mlj.goums.ac.ir/article-1-1497-en.htmlTest; https://doaj.org/toc/2538-4449Test

الوصول الحر: https://doaj.org/article/1ca127a8b78a42b88d61caf51c6a8595Test

المؤلفون: Suman Doddamani, Muragendraswami Astagimath, Raviraja Aryapu, Vishwanath Patil

المصدر: APIK Journal of Internal Medicine. 11:33

مصطلحات موضوعية: General Medicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::52991a2e4507b7fbbda37006f96a2294Test
https://doi.org/10.4103/ajim.ajim_18_22Test